Immunotherapy for Merkel cell carcinoma: a turning point in patient care

Merkel Cell carcinoma (MCC) is a rare but aggressive cancer, with an estimated disease-associated mortality as high as 46%. MCC has proven to be an immunologically responsive disease and the advent of immune checkpoint inhibitors has changed the treatment landscape for patients with advanced MCC. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Isaac S., Bhatia, Shailender, Kaufman, Howard L., Lipson, Evan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865292/
https://www.ncbi.nlm.nih.gov/pubmed/29566749
http://dx.doi.org/10.1186/s40425-018-0335-9
Descripción
Sumario:Merkel Cell carcinoma (MCC) is a rare but aggressive cancer, with an estimated disease-associated mortality as high as 46%. MCC has proven to be an immunologically responsive disease and the advent of immune checkpoint inhibitors has changed the treatment landscape for patients with advanced MCC. In this review, we discuss the rationale for the use of immune checkpoint inhibition, review current single agent therapies tested in and approved for MCC, and discuss emerging immunotherapeutic options for these patients.

Ejemplares similares